Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) directly influence thrombus formation and degradation and thereby risk for arterial thrombosis. Activation of the renin-angiotensin system has been linked to the production of PAI-1 expression via the angiotensin II type 1 receptor (AT1R). In addition, bradykinin can induce the release of t-PA through a B2 receptor mechanism. In the present study, we aimed to investigate the epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels in a large population-based sample (n = 2527). We demonstrated a strong significant interaction within genetic variations of the bradykinin B2 gene (P = 0.002) and between ACE and bradykinin B2 (p = 0.003) polymorphisms on t-PA levels in females. In males, polymorphisms in the bradykinin B2 and AT1R gene showed the most strong effect on t-PA levels (P = 0.006). In both females and males, the bradykinin B2 gene interacted with AT1R gene on plasma PAI-1 levels (P = 0.026 and P = 0.039, respectively). In addition, the current study found a borderline significant interaction between PAI 4G5G and ACE I/D on plasma t-PA and PAI-1 levels. These results support the idea that the interplay between the renin-angiotensin, bradykinin, and fibrinolytic systems might play an important role in t-PA and PAI-1 biology.
The endogenous fibrinolytic system describes a complex process resulting in the hydrolytic cleavage of fibrin by plasmin to promote clot dissolution and generate fibrin degradation products. This system helps protect the circulation from intravascular fibrin formation and thrombosis that would otherwise lead to vessel occlusion and tissue ischemia [1, 2] . The efficacy of plasminogen activation and fibrin degradation is largely determined by the balance between local concentrations of tissue-type plasminogen activator (t-PA) and its cognate inhibitor, plasminogen activator inhibitor type 1 (PAI-1). There is substantial evidence indicating that plasma t-PA and PAI-1 are regulated in part by the renin-angiotensin system (RAS) [3] . Angiotensin II promotes the synthesis of PAI-1 in vitro [4, 5] . Furthermore, ACE inhibitors have been shown to reduce plasma PAI-1 levels in patients with postmyocardial infarction [6] , in hypertensive subjects [7] , and in postmenopausal females [8] . Conversely, bradykinin is a potent stimulator for t-PA in humans [9] and ACE inhibition augments bradykinin-induced t-PA release from the arterial vasculature [10, 11] .
Interactions between the RAS, bradykinin, and fibrinolytic systems on t-PA and PAI-1 levels may explain at least part of the relationship between those systems and cardiovascular disease and the beneficial effects of ACE inhibition on thrombotic Genomics 89 (2007) 362 -369 www.elsevier.com/locate/ygeno events. Indeed, prior studies demonstrated interactions between genes from the fibrinolytic system and RAS on levels of t-PA and PAI-1 [12] [13] [14] . However, these studies either were performed in selected high-risk populations or had small sample sizes. In addition, no study has yet investigated the interplay between genes from the RAS, bradykinin, and fibrinolytic systems on plasma levels of t-PA and PAI-1 in a single study. Therefore, the aim of the present study was to investigate the effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma levels of t-PA and PAI-1 in a large population-based sample, explicitly examining two-way epistatic interactions.
Results
Clinical characteristics of both females and males are listed in Table 1 . Except for body mass index and total cholesterol levels, all characteristics are significantly different between females and males.
Figs. 1 and 2 summarize the results of the statistical tests for epistasis in the form of network diagrams for females and males, respectively. Only significant results with suggestive or strong evidence for interaction are illustrated. Supplementary Tables 1  and 2 present the P values for all statistical tests performed.
In females, we found significant evidence for fibrinolytic-RAS, fibrinolytic-bradykinin, RAS-bradykinin, and bradykininbradykinin interaction effects on plasma t-PA levels. A total of 7 gene-gene interactions were detected out of the 15 comparisons. We also found significant evidence for fibrinolytic-RAS, fibrinolytic-bradykinin, and RAS-bradykinin interaction effects on plasma PAI-1 levels. A total of 6 gene-gene interactions were detected out of the 15 comparisons.
In males, we found significant evidence for fibrinolytic-RAS, RAS-bradykinin, RAS-RAS, and bradykinin-bradykinin interaction effects on plasma t-PA levels. A total of 6 gene-gene interactions were detected out of the 15 comparisons. We also found significant evidence for fibrinolytic-RAS, fibrinolyticbradykinin, RAS-bradykinin, and bradykinin-bradykinin interaction effects on plasma PAI-1 levels. A total of 7 gene-gene interactions were detected out of the 15 comparisons.
Common to both traits and both genders were significant interactions between genes from the bradykinin system and the RAS, but the specific interaction detected differed between gender. Fig. 3 illustrates the mean ln t-PA and mean ln PAI-1 levels by genotype combination in females and males. In each case, there is evidence for crossing of the lines that is characteristic of epistasis. That is, the effect of any one polymorphism on either t-PA or PAI-1 levels is dependent on the genotypes at the second polymorphism.
Thus, for both traits and both genders we found evidence for multiple epistatic effects using either suggestive or strong supporting statistical evidence. A total of 24 significant genegene interactions were observed out of 60 possible. Of the 24, 10 involved dominant-recessive interactions, 7 involved recessive-recessive interactions, 4 involved dominant-additive interactions, 2 involved recessive-additive interactions, and 1 involved a dominant-dominant interaction. It is important to note that the interactions reported here and summarized in Figs. 1 and 2 are only the most significant of those examined; all results are shown in Supplementary Tables 1 and 2 . For example, the BDKRB2 C58T by ACE I/D interaction on t-PA levels in females reported in Figs. 1 and 3 involved a dominant by additive effect with a P value of 0.003. However, the additive by dominant (P = 0.025), dominant by dominant (P = 0.007), and additive by additive (P = 0.018) were all statistically significant at an α = 0.025 level. The magnitude of each interaction effect was on the order of 1% variation explained. This is consistent with a genetic architecture in which many polymorphisms account for the heritability of the trait. As such, it will be important to explore higher-order models.
It is important to note that there are many differences between females and males (see Figs. 1 and 2 ). For example, there was strong evidence for an interaction effect of the BDKRB2 exon 1 I/D and BDKRB2 C181T polymorphisms on t-PA levels in females (P = 0.002) but not in males (P > 0.10). As an additional example, we observed strong evidence for an interaction effect of the PAI-1 4G/5G and BDKRB2 C181T polymorphisms on PAI-1 levels in males (P = 0.023) but not in females (P > 0.10). These results are consistent with the gender-specific univariate effects of these polymorphisms [31] . One similarity in females and males is that in subjects homozygous for AT1R A1166C, PAI-1 levels are lower in subjects heterozygous for BDKRB2 C58T in both females and males (Fig. 3) .
Discussion
The present study examined the relationships between genetic polymorphisms in the RAS, bradykinin, and fibrinolytic systems on plasma levels of t-PA and PAI-1 in a large population-based sample. We observed interactions between genetic polymorphisms of the three different systems both on plasma t-PA levels and on plasma PAI-1 levels. Interestingly, 1 . Polymorphisms of the renin-angiotensin, bradykinin, and fibrinolytic system show significant interactions on plasma t-PA and PAI-1 levels among females. Only the significant (P < 0.025) and borderline significant (P < 0.10) interactions are presented. The lines illustrate the interactions between genes and line thickness is inversely related to the significance level. The model of inheritance is given in parentheses. A, additive; D, dominant; R, recessive. For example, the BDKRB2 exon 1 I/D by BDKRB2 C181T interaction on t-PA levels involved a dominant by recessive effect with a P value of 0.002. Fig. 2 . Polymorphisms of the renin-angiotensin, bradykinin, and fibrinolytic system show significant interactions on plasma t-PA and PAI-1 levels among males. Only the significant (P < 0.025) and borderline significant (P < 0.10) interactions are presented. The lines illustrate the interactions between genes and line thickness is inversely related to the significance level. The model of inheritance is given in parentheses. A, additive; D, dominant; R, recessive. For example, the AT1R A1166C by BDKRB2 C181T interaction on t-PA levels involved a dominant by additive effect with a P value of 0.006. these interactions appear to be different among females and males.
Epistatic effects of RAS and bradykinin systems on plasma t-PA and PAI-1 levels
The effect of RAS polymorphisms on t-PA and PAI-1 levels has been studied previously, but no data are available about the joint effects of RAS and bradykinin gene polymorphisms on markers of the fibrinolytic system. The I/D polymorphism of the ACE gene has been associated with PAI-1 levels in apparently healthy persons [13] , in patients with hypertension [15] , and in patients attending a metabolic ward [14] . In contrast, no relation between ACE I/D polymorphism on PAI-1 levels could be detected in the National Heart, Lung, and Blood Institute Family Heart Study [16] . In vitro data have shown that the angiotensin II-induced PAI-1 expression may be mediated by the angiotensin II type 1 receptor [3, 17] .
In the present study, polymorphisms of the RAS and bradykinin genes showed epistatic effects on both PAI-1 as t-PA levels among females and males. In contrast to the aforementioned relation between RAS gene polymorphisms and the fibrinolytic system, less is known about the relation between bradykinin gene polymorphisms and t-PA and PAI-1 levels. In addition to being an inflammatory mediator, bradykinin is a potent endothelial cell stimulant that can induce the acute release of t-PA from the endothelium through a B2 receptor mechanism [18] . ACE inhibition augments the effects of bradykinin on the B2 receptor, which leads to t-PA release from the endothelium [10] . In addition, a recent study showed that ACE inhibition reduced PAI-1 expression in tubular epithelial cells by bradykinin action [19] . To our knowledge, no study investigated the effect of bradykinin gene polymorphisms or the interaction between RAS and bradykinin gene polymorphisms on t-PA and PAI-1 levels. In the present study, we demonstrate several significant interactions between genetic variations of the bradykinin B2 gene on t-PA levels. These findings confirm results from prior studies that bradykinin plays an important role on t-PA levels. In addition, a consistent interaction was present between the RAS and bradykinin systems on plasma levels of t-PA and PAI-1 in both genders, although the nature of the interactions differed.
Epistatic effects of PAI 4G5G on plasma t-PA and PAI-1 levels Despite the strong univariate relation between the PAI 4G5G polymorphism and PAI levels [20] , the PAI 4G/5G polymorphism did not interact very strongly with the RAS and bradykinin gene polymorphisms. However, a consistent interaction was present between the PAI 4G5G and the ACE I/D polymorphisms in both females and males. This epistatic effect between both systems has been described previously in patients attending a metabolic ward [14] and a normotensive unrelated population [21] . Angiotensin II may regulate PAI-1 levels in the general population and inhibition of renin-angiotensin system has been shown to reduce PAI-1 levels [8] . These data and the current results support the idea that the two systems interact. This therefore could potentially explain the beneficial effects of ACE inhibition on thrombotic events.
Gender differences in epistatic effects on t-PA/PAI-1 levels
It is well known that risk for cardiovascular disease differs among gender and several mechanisms have been proposed to account for this difference [22] . One of the main mechanisms might be the gender difference in fibrinolysis and thereby thrombotic state. The THROMBO investigators found gender differences in several thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction [23] . Several study groups have postulated that the cardioprotective effect of estrogen may be mediated, in part, by an increase in fibrinolytic potential. Subjects with lower estrogen have a lower fibrinolytic potential (higher PAI-1 levels) than subjects with a high estrogen status [24] . This relation between estrogen and fibrinolysis has been related to the capacity of estrogen to regulate the RAS system [25, 26] . In addition, ACE inhibition therapy has been shown to increase basal t-PA release in females but not in males [11] . Furthermore, side effects associated with ACE inhibition such as coughing occur more frequently in females than in males. The mechanism of cough associated with ACE inhibitor therapy is related to the bradykinin metabolism, which again is related to t-PA release in humans [27, 28] . These studies and the current results suggest sex-specific differences in epistatic effects of RAS, bradykinin, and fibrinolytic system on plasma t-PA and PAI-1 levels. Future studies are needed to investigate whether gender-specific therapeutics need to be developed protect against disease processes that show clear sex difference in their etiology and progression.
Future considerations
This study supports the idea that epistasis is a ubiquitous component of the genetic architecture of human traits [29] . Future studies need to address several issues to understand the complicated epistatic effects of polymorphisms in the RAS, bradykinin, and fibrinolytic genes. First, the nature and biological interpretation of the interactions need to be determined. Although this is very important, traversing the hierarchical divide between statistical epistasis, observed as deviations from additivity in a linear model that summarizes specific patterns of genotypes and phenotypes across multiple individuals in a sample, and biological epistasis, observed as biomolecular interactions at the cellular level in an individual, is very difficult and will likely only be possible when all etiological factors can be measured [30, 31] . Second, in addition to the described systems, future studies need to consider other systems that might be implicated in arterial thrombosis. Third, this paper focused on two-way interactions, but high-order interactions are certainly possible, but may be hard to detect due to limits of the traditional statistical approaches [32] . Finally, we need to consider the context of the environment on the genetic effects (gene-environment interactions). This approach will lead to a better understanding of the genetic architecture of fibrinolytic factors and subsequently of the development of arterial thrombosis in human.
In conclusion, the results of this large population-based study support the idea that the interplay between the reninangiotensin, bradykinin, and fibrinolytic systems might have an important role in t-PA and PAI-1 biology and thereby arterial thrombosis.
Materials and methods

Study population
The sample analyzed in this study was obtained from the ongoing prospective Prevention of Renal and Vascular End-Stage Disease (PREVEND) study. The PREVEND study was designed to investigate prospectively the natural course of albuminuria and its relation to renal and cardiovascular disease in a large cohort drawn from the general population. Details of the study protocol have been described previously [33, 34] . In summary, during 1997-1998, all 85,421 inhabitants of the city of Groningen, the Netherlands, from the ages of 28 to 75 years old, were sent a one-page postal questionnaire (regarding demographics, use of medication, and pregnancy) and a vial to collect an early morning urine sample. A total of 40,856 subjects responded. After exclusion of subjects with type 1 diabetes mellitus, females who were possibly pregnant, and males and females not able or willing to participate, a total of 6000 subjects with a urinary albumin concentration ≥10 mg l − 1 and a random control sample of subjects with a urinary albumin concentration < 10 mg l − 1 (n = 2592) completed the screening protocol and formed the baseline PREVEND cohort (n = 8592). From this cohort, we selected a random sample of 2527 subjects (1338 females and 1189 males) as being representative of the entire population from which the PREVEND cohort was selected. These individuals were used in the present study to explore t-PA and PAI-1 levels in the general population. In this group, t-PA and PAI-1 levels were missing in 39 (1.5%) and 42 (1.7%) subjects, respectively. The PREVEND study was approved by the local medical ethics committee and conducted in accordance with the guidelines of the Declaration of Helsinki.
Laboratory measurements
Blood samples were obtained during the morning in all subjects to minimize variability due to circadian rhythms, but day-to-day variability of t-PA and PAI-1 levels was not addressed in the current study. Plasma levels of t-PA and PAI-1 were measured using an ELISA kit from Technoclone Gmbh (Vienna, Austria). The assays measured both free t-PA and PAI-1 and their complexes. In brief, diluted plasma samples were added to a 96-well microtiter plate coated with antibodies to either t-PA or PAI and incubated for 2 h at 37°C. After being washed, a peroxidase-labeled second antibody to either t-PA or PAI-1 was added to the wells and the plate was incubated for 1 h at 37°C. After washing, substrate (ABTS) was added. The reaction was stopped after 30 min and the absorbance at 405 nm was measured. Each assay included calibrants (1.0-20 ng/ml for t-PA and 1.0-25 ng/ml for PAI-1) and two quality control samples. The lower limit of quantification was 1.0 ng/ml for t-PA and 1.5 ng/ml for PAI-1. Assays not meeting quality control standards were not included in the analyses.
Serum cholesterol was determined by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA). HDL-cholesterol was measured with a homogeneous method (direct HDL, No. 7D67, AEROSET System; Abbott Laboratories).
Measurement of genetic polymorphisms
The AT1R A1166C (rs5186), the BDKRB2 C-58T (rs1799722) and C181T (rs1046248), and PAI 4G/5G (rs1799768) polymorphisms were analyzed using TaqMan-MGB probes and PCR primers, designed through the Assay-by-Design service (Applied Biosystems). TaqMan assays were carried out according to the manufacturer's recommendations on an ABI 7900HT apparatus and results were analyzed with SDS 2.0 genotype calling software (Applied Biosystems).
The ACE I/D (rs4646994) and the BDKRB2 exon 1 insertion/deletion polymorphisms were also analyzed by PCR amplification, with one of the primers having a fluorescent label, and subsequent determination of the lengths of the PCR products on a capillary sequencer. Primers were picked with the aid of the online Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). After PCR cycling, samples of the above assays were pooled and separated on a MegaBACE 1000 sequencer. Fragments were analyzed with Genetic Profiler 2.0 software (Amersham Biosciences).
Statistical analysis
Continuous data are reported as means ± standard deviation. Categorical data are presented as per group percentages. Differences in continuous characteristics between genders were evaluated by Student's t test. Differences in categorical data between genders were compared with the χ 2 test. The primary goal of the statistical analysis was to test the null hypothesis that the effect of any one polymorphism on t-PA or PAI-1 levels is not dependent on one of the other polymorphisms. We used a two-way analysis of variance (ANOVA) to test this null hypothesis. A statistically significant interaction term was considered evidence in favor of the alternative hypothesis of epistasis or gene-gene interaction. All tests were carried out in females and males separately since the distributions of t-PA or PAI-1 have previously been shown to be gender specific [34] .
All genotypes were coded (AA = 0, Aa = 1, aa = 2) to capture additive effects (0 = AA or Aa, 1=aa), to capture dominant effects and (0 = AA, 1=Aa or aa), and to capture recessive effects. All possible pairs of genotypes were evaluated using ANOVA. The nine possible interaction effects tested included additive by additive, additive by dominant, additive by recessive, dominant by additive, dominant by dominant, dominant by recessive, recessive by additive, recessive by dominant, and recessive by recessive. For each pair of polymorphisms, all nine interactions were tested and the most significant result was reported. We did not limit the analysis by eliminating rare genotypes since the sample size was sufficient in most cases to estimate the interaction effects.
Within each gender and for each trait, we tested 15 possible pairs of polymorphisms for epistatic effects. Within each of the 15 comparisons we tested the 9 possible interactions (e.g., additive by additive). Thus, there are multiple statistical tests at the polymorphism level (15 tests) and at the genotype coding level (9 tests). We present and use here two different levels of statistical significance for making inferences about the epistatic effects of the polymorphisms studied. First, we used an uncorrected significance level of α = 0.10 as suggestive evidence for interaction. This liberal significance was selected for several reasons. First, the pathways, genes, and polymorphisms selected for study are all strong candidates for influencing t-PA and PAI-1 biochemistry. Second, we used a more conservative significance level of α = 0.025 as strong evidence for interaction. This more conservative significance level was derived from 1000 Monte Carlo simulations under the null hypothesis. For each of the 1000 simulations, we recorded the smallest P values selected from the 9 different interaction tests. From this null distribution we determined that a minimum P value of approximately 0.025 or smaller was expected 10% of the time. All P values for all tests performed are reported so the reader may make their own interpretations regarding biological significance. We did not perform corrections for multiple testing because the universal null hypothesis that is assumed for a Bonferroni-type correction does not apply to this study [35] . In addition, this is the first study to examine interactions among genes from the fibrinolytic, RAS, and bradykinin systems. As such, we are more concerned about type II errors (false-negatives) than type I errors (false-positives). This is especially true since ANOVA has less power to detect interactions than independent main effects.
